"Warfarin is a blood thinner that is commonly prescribed to patients to prevent lifethreatening blood clots. Despite its longtime use warfarin remains tricky to dose because a persons genetic makeup influences how the drug is processed in the body. Too much warfarin can cause internal bleeding too little warfarin fails to prevent blood clots.    Now a new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin Coumadin and others is safer  producing fewer adverse events such as hemorrhage  when key elements of a patients genetic makeup are considered.    The research published Sept.  in the Journal of the American Medical Association reports results from the clinical trial known as GIFT Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis.    Physicians have been prescribing warfarin since the Eisenhower administration said first author Brian F. Gage MD a professor of medicine at Washington University School of Medicine in St. Louis. Its a widely used anticoagulant but it causes more major adverse events than any other oral drug. Thousands of patients end up in the emergency department or hospital because of warfarininduced bleeding. But we continue to prescribe it because it is highly effective reversible and inexpensive. So our goal is to make warfarin safer. GIFT showed that precisionmedicine based on clinical factors and three genes improves the safety of initiating warfarin therapy.    Patients in the trial were randomly assigned to one of two groups. One group received warfarin dosing based on standard factors such as age height and weight the second group was dosed based on these clinical factors plus genetic variants. Participating sites in the trial included Washington University School of Medicine Hospital for Special Surgery in New York Intermountain Healthcare University of Utah and Rush University Medical Center.    Of the  patients who were dosed in the traditional manner  experienced at least one adverse event . percent. Of the  patients whose warfarin dosing was guided by genetic testing  experienced an adverse event . percent. Compared with patients receiving traditional warfarin dosing patients dosed with the genetic approach had a  percent reduction in adverse events which was statistically different. The adverse events were bleeding formation of blood clots in the veins and warfarin overdoses. No patient died during the trial.    Earlier studies looking at whether genetic testing could improve warfarin dosing had produced conflicting results. However these studies were smaller and considered fewer genes than GIFT. GIFT enrolled  patients age  and older at high risk of blood clots because they underwent hip or kneereplacement surgeries.    Unlike prior studies GIFT took into account genetic variants in three genes for  days of warfarin therapy. Genetic variants were assessed on a commercial platform called GenMarkDx. Variants in one gene affect vitamin K recycling. Variants in another gene affect warfarin sensitivity. Variants in the third gene alter warfarin metabolism in the liver and can cause an overdose if the dose is not adjusted soon enough.    There are additional genetic variants that may help to guide warfarin dosing especially among patients with African ancestry Gage said. In the future we hope to quantify how these variants affect warfarin.    Gage also noted how healthcare costs relate to dosing warfarin in a genetically guided manner. Although genetic testing is more expensive than clinical dosing the cost is falling he said. In our study we estimated that genetic testing costs less than  per person which is less than one month of a newer anticoagulant.          This work was supported by the National Heart Lung and Blood Institute NHLBI and the National Center for Advancing Translational Sciences NCATS of the National Institutes of Health NIH grant numbers RHL and ULTR the Centers for Medicare and Medicaid Services grant number CAGN and GenMarkDx which supplied instrumentation.    Gage BF Bass AR Lin H Woller SC Stevens SM AlHammadi N Li J Rodriguez Jr. T Miller JP McMillin GA Pendleton RC Jaffer AK King CR DeVore B PorcheSorbet R Napoli L Merritt K Thompson AM Hyun G Anderson JL Hollomon W Barrack RL Nunley RM Moskowitz G DavilaRoman V and Eby CS for the GIFT investigators. Effect of genotypeguided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty the GIFT randomized clinical trial. Journal of the American Medical Association. Sept.  .    Washington University School of Medicines  employed and volunteer faculty physicians also are the medical staff of BarnesJewish and St. Louis Childrens hospitals. The School of Medicine is one of the leading medical research teaching and patientcare institutions in the nation currently ranked seventh in the nation by U.S. News  World Report. Through its affiliations with BarnesJewish and St. Louis Childrens hospitals the School of Medicine is linked to BJC HealthCare."